Roche phase 3 hits goal in subgroup of prostate cancer patients

Roche designed the trial primarily to assess whether giving ipatasertib in combination with Johnson & Johnson’s Zytiga improves PFS in patients with metastatic castrate-resistant prostate cancer. The trial generated mixed results against that primary endpoint.